Drug Type Small molecule drug |
Synonyms I-037, LT 3001, LT-3001 + [1] |
Target |
Mechanism Free radicals inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H51N7O8 |
InChIKeyHCQSIGZMBBOVBZ-NHKCCNDQSA-N |
CAS Registry1639303-73-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stroke | Phase 2 | US | 21 Jul 2022 | |
Acute Ischemic Stroke | Phase 2 | US | 27 Jan 2020 | |
Acute Ischemic Stroke | Phase 2 | TW | 27 Jan 2020 | |
Androgen-Insensitivity Syndrome | Phase 2 | US | 27 Jan 2020 | |
Androgen-Insensitivity Syndrome | Phase 2 | TW | 27 Jan 2020 |
NCT05403866 (NEWS) Manual | Phase 2 | - | rzerldftiv(yztaowdbmd) = LT3001 注射液总体安全耐受性良好。 dgcziqkpot (gvulzgqdhw ) | Positive | 30 Nov 2024 | ||
Phase 2 | 24 | Odatroltide (LT3001) 0.025 mg/kg | ndidvdhdjw(ueoeyiwtwl) = foidhsqmsm eprpewdwlq (lmnykcfasr ) View more | Positive | 01 Jan 2024 | ||
Placebo | ndidvdhdjw(ueoeyiwtwl) = aokbebxaxh eprpewdwlq (lmnykcfasr ) View more | ||||||
Phase 2 | 24 | pcezunjegc(xmjwbvhafc) = no evidence of increased risk zjkcjaztup (jyfozhgiyy ) | Positive | 03 Aug 2021 | |||
Placebo |